BCAX
Bicara Therapeutics Inc. Common Stock
1W: -4.1%
1M: +19.4%
3M: +2.4%
YTD: +12.4%
1Y: +48.5%
$18.41
-0.38 (-2.02%)
After Hours: $20.02 (+1.61, +8.72%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$22.6M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.0B
52W Range7.8-20.25
Volume851,570
Avg Volume487,664
Beta-0.77
Dividend—
Analyst Ratings
Company Info
CEOClaire Mazumdar Clemon
Employees55
SectorHealthcare
IndustryBiotechnology
IPO Date2024-09-13
Websitebicara.com
116 Huntington Avenue
Boston, MA 02116
US
Boston, MA 02116
US
617-468-4219
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Latest News
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Bleakley Financial Group LLC Makes New $481,000 Investment in Bicara Therapeutics Inc. $BCAX
Bicara Therapeutics Inc. (BCAX) Discusses Ficerafusp Alfa Clinical Data and Less Frequent Dosing in First-Line HPV-Negative Head and Neck Squamous Cell Carcinoma Transcript
Bicara Therapeutics prices offering to raise $150M
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Mazumdar Claire | M-Exempt | 1,596 | $3.79 | 2026-03-20 |
| Mazumdar Claire | S-Sale | 1,596 | $18.95 | 2026-03-20 |
| Mazumdar Claire | M-Exempt | 1,596 | $3.79 | 2026-03-20 |
| Mazumdar Claire | M-Exempt | 6,905 | $3.79 | 2026-03-19 |
| Mazumdar Claire | S-Sale | 6,905 | $18.78 | 2026-03-19 |